Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 4251.28%.

  • Aligos Therapeutics' EBITDA Margin fell 27172000.0% to 4251.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 3300.95%, marking a year-over-year decrease of 17677900.0%. This contributed to the annual value of 3636.25% for FY2024, which is 26988400.0% down from last year.
  • As of Q3 2025, Aligos Therapeutics' EBITDA Margin stood at 4251.28%, which was down 27172000.0% from 1646.63% recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' EBITDA Margin peaked at 13853.38% during Q1 2025, and registered a low of 13576.9% during Q4 2024.
  • Over the past 5 years, Aligos Therapeutics' median EBITDA Margin value was 1394.9% (recorded in 2022), while the average stood at 1867.09%.
  • In the last 5 years, Aligos Therapeutics' EBITDA Margin crashed by -121909300bps in 2024 and then skyrocketed by 188868100bps in 2025.
  • Aligos Therapeutics' EBITDA Margin (Quarter) stood at 10085.01% in 2021, then soared by 94bps to 611.93% in 2022, then plummeted by -126bps to 1385.96% in 2023, then crashed by -880bps to 13576.9% in 2024, then skyrocketed by 69bps to 4251.28% in 2025.
  • Its last three reported values are 4251.28% in Q3 2025, 1646.63% for Q2 2025, and 13853.38% during Q1 2025.